The medication slows down the emptying of your stomach, which makes you feel full longer and helps your body process sugar better, often leading to decreased food intake and weight loss
Methods: This is a retrospective, observational, multicenter study which has included adult patients who received an ICI (anti-PD1, anti-PDL1 or anti-CTLA4) after LT for hepatocellular carcinoma (HCC) recurrence or a de novo tumor
In practice, clinicians prioritize reviewing concurrent medications, considering dose-adjustment or slower titration, and prescribing anti-nausea agents when needed to maintain therapy adherence
Mapping the effectiveness and risks of Glp-1 receptor agonists
Post-injection care includes proper disposal of the needle in an FDA-cleared sharps container (or puncture-resistant household container if an FDA-cleared container is unavailable)